Market Place
Sourcing Support
Fractyl Health Presents Preclinical Data on Rejuva® Gene Therapy
04 Nov 2024 //
GLOBENEWSWIRE
Fractyl Health Shows Durable Weight Loss at ObesityWeek® 2024
04 Nov 2024 //
GLOBENEWSWIRE
Fractyl Health to Report Q3 2024 Results on Nov 12, 2024
29 Oct 2024 //
GLOBENEWSWIRE
Fractyl Health Presents Weight Maintenance Data at ObesityWeek
28 Oct 2024 //
GLOBENEWSWIRE
Fractyl Health to Present at Chardan’s Genetic Medicines Conference
24 Sep 2024 //
GLOBENEWSWIRE
Fractyl Health to Participate in Upcoming September Investor Conferences
03 Sep 2024 //
GLOBENEWSWIRE
Fractyl Health Reports Q2 2024 Financial Results And Business Updates
14 Aug 2024 //
GLOBENEWSWIRE
Fractyl Health Announces Clinical Results From German Registry
08 Aug 2024 //
GLOBENEWSWIRE
Fractyl Health To Report Q2 2024 Results And Updates On August 14
07 Aug 2024 //
GLOBENEWSWIRE
Fractyl Health`s Revita Gets FDA Breakthrough Device Designation
30 Jul 2024 //
GLOBENEWSWIRE
Fractyl Health to Present at Piper Sandler 2nd Annual Virtual Obesity Day
25 Jun 2024 //
GLOBENEWSWIRE
Fractyl Health advances Weight Maintenance Pipeline and business updates.
24 Jun 2024 //
GLOBENEWSWIRE
Fractyl Health Preclinical Data Rejuva® GLP-1 Therapy ADA 84th Session
23 Jun 2024 //
GLOBENEWSWIRE
Fractyl Presents Rejuva® Obesity Preclinical Data At ADA 2024
29 May 2024 //
GLOBENEWSWIRE
Fractyl Presents GLP-1 Pancreatic Gene Therapy Data At DDW
20 May 2024 //
GLOBENEWSWIRE
Fractyl Presents Revita German Registry Update For Advanced T2D
13 May 2024 //
GLOBENEWSWIRE
Fractyl Health Q1 2024 Financials, Business Updates
13 May 2024 //
GLOBENEWSWIRE
Fractyl Health to Present at BofA Securities 2024 Health Care Conference
08 May 2024 //
GLOBENEWSWIRE
Fractyl Q1 2024 Results And Updates On May 13
07 May 2024 //
GLOBENEWSWIRE
Fractyl: Presentations At DDW 2024, DDG On Type 2 Diabetes Treatments
30 Apr 2024 //
GLOBENEWSWIRE
Fractyl Health Appoints Kimber as COO & Conducts Two Pivotal Studies for Revita
02 Apr 2024 //
GLOBENEWSWIRE
Fractyl Health Receives FDA IDE Approval for the Revita
01 Apr 2024 //
GLOBENEWSWIRE
Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
Fractyl Health Announces New Results From Its Rejuva® Platform
12 Mar 2024 //
GLOBENEWSWIRE
UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform
12 Mar 2024 //
GLOBENEWSWIRE
Fractyl Health Appoints Samuel Conaway to Its Board of Directors
20 Feb 2024 //
GLOBENEWSWIRE
Fractyl Health raises $110 mln in US IPO
02 Feb 2024 //
REUTERS
Fractyl Health targets up to $762 mln valuation in US IPO
02 Feb 2024 //
REUTERS
Fractyl Health valued at $654.6 mln in tepid debut
02 Feb 2024 //
REUTERS
Alto, Fractyl head to public markets with IPOs north of $100M
02 Feb 2024 //
FIERCE BIOTECH
Fractyl Health Announces Pricing of Initial Public Offering
01 Feb 2024 //
GLOBENEWSWIRE
Fractyl Announces Nomination of RJVA-001 as First Candidate in Gene Therapy Platform
05 Jan 2024 //
GLOBENEWSWIRE
Hoping its GLP-1 gene therapy can beat Wegovy, Fractyl plans IPO
15 Dec 2023 //
FIERCE BIOTECH
Fractyl Health Announces New Pooled Analysis From Revita® Clinical Studies
14 Dec 2023 //
GLOBENEWSWIRE
Fractyl Health files for IPO to back gene therapy
14 Dec 2023 //
ENDPTS
Fractyl Health Expands Landmark Academic-Industry Collaboration
16 Nov 2023 //
GLOBENEWSWIRE
Fractyl`s GLP-1 obesity gene therapy outdoes semaglutide—in mice
05 Oct 2023 //
FIERCE BIOTECH
Fractyl Health Demonstrated Improvement in Weight Loss in Studies of its Rejuva
04 Oct 2023 //
BUSINESSWIRE
Fractyl Health to Present Pioneering Data on Revita® and Rejuva® Programs
28 Sep 2023 //
BUSINESSWIRE
Fractyl Health Welcomes Dr. Timothy Kieffer as Chief Scientific Officer
14 Sep 2023 //
BUSINESSWIRE
Fractyl Health Reports Durable Improvement in Glucose Control & Weight Loss
26 Jun 2023 //
BUSINESSWIRE
Fractyl Health Unveils Results for its Rejuva® Pancreatic Gene Therapy Platform
18 May 2023 //
BUSINESSWIRE
Fractyl Health Announces Commercial Availability of Revita in Germany
07 Feb 2023 //
BUSINESSWIRE
Fractyl Health Announced Positive Proof-of-Concept Data of GLP-1 Gene Therapy
05 Dec 2022 //
BUSINESSWIRE
Fractyl Health Presents New Mechanistic Data on Revita® DMR in Type 2 Diabetes
22 May 2022 //
BUSINESSWIRE
Fractyl Health Announces FDA IDE Approval to Begin Revitalize-2 Pivotal in T2D
04 Apr 2022 //
BUSINESSWIRE
